Alta Smit, MD Biologische Heilmittel Heel GmbH, Dr-Reckeweg-Strasse 2–4, Baden-Baden, German

Bioregulatory medicine may be used as basic therapy or in combination with classical allopathic therapy in relation to a patient’s autoregulatory ability. Bioregulatory drugs simultaneously act upon perturbations in impaired autoregulatory networks and upon many targets. The bioregulatory drugs may be considered to be plant and other biological extracts at low concentrations, in which a large number of active substances make them ideal candidates for multidirectional action, and the antihomotoxic drugs may be deemed to be those designed in accordance with the principles of homotoxicology.

homeostatic inflammation
bioregulatory drugs
antihomotoxic drugs

  1. Chovatiya R., Medzhitov R. Stress, inflammation, and defense of homeostasis. Mol. Cell. 2014; 54 (2): 281–8.
  2. Miyake K., Kaisho T. Homeostatic inflammation in innate immunity. Curr.Opin.Immunol., 2014; 30 (10): 85–90.
  3. Cheng L.E., Locksley R.M. Allergic inflammation — innately homeostatic. Cold. Spring.Harb.Perspect.Biol., 2015; 7 (3): a016352.
  4. Medzhitov R. Inflammation 2010: new adventures of an old flame. Cell, 2010; 140 (6): 771–6.
  5. Simko G.I., Gyurko D., Veres D.V., Nanasi T., Csermely P. Network strategies to understand the aging process and help age-related drug design. Genome Med., 2009; 1 (9): 90.
  6. Serhan C.N., Petasis N.A. Resolvins and protectins in inflammation resolution. Chem. Rev., 2011; 111 (10): 5922–43.
  7. Lawrence T., Gilroy D.W. Chronic inflammation: a failure of resolution? Int. J. Exp.Pathol., 2007; 88 (2): 85–94.
  8. Serhan C.N., Chiang N., Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev.Immunol., 2008; 8 (5): 349–61.
  9. Conaghan P.G. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol.Int., 2012; 32 (6): 1491–502.
  10. Nathan C., Ding A. Nonresolving inflammation. Cell, 2010; 140 (6): 871–82.
  11. Kotas M.E., Medzhitov R. Homeostasis, Inflammation and disease susceptibility. Cell, 2015; 160 (5): 816–27.
  12. McDade T.W. Early environments and the ecology of inflammation. Proc. Natl. Acad. Sci. USA, 2012; 109 (suppl): 17281–8.
  13. Itoh M., Suganami T., Hachiya R., Ogawa Y. Adipose tissue remodeling as homeostatic inflammation. Int. J.Inflam., 2011; 2011: 720926.
  14. Nathan C. Points of control in inflammation. Nature, 2002; 420 (6917): 846–52.
  15. Mann C.J., Perdiguero E., Kharraz Y. et al. Aberrant repair and fibrosis development in skeletal muscle. Skelet. Muscle, 2011; 1 (1): 21.
  16. Serrano A.L., Mann C.J., Vidal B., Ardite E., Perdiguero E., Munoz-Canoves P. Cellular and molecular mechanisms regulating fibrosis in skeletal muscle repair and disease. Curr. Top. Dev.Biol., 2011; 96: 167–201.
  17. Holt A.P., Salmon M., Buckley C.D., Adams D.H. Immune interactions in hepatic fibrosis. Clin. Liver. Dis., 2008; 12 (4): 861–82.
  18. Ahn A.C., Tewari M., Poon C-S., Phillips R.S. The clinical applications of a systems approach. PLoS. Med., 2006; 3 (7): e209.
  19. Wild C.P. Complementing the genome with an «exposome»: the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol. Biomarkers Prev., 2005; 14 (8): 1847–50.
  20. Miller G.W., Jones D.P. The nature of nurture: refining the definition of the exposome. Toxicol.Sci., 2014; 137 (1): 1–2.
  21. Wishart D., Arndt D., Pon A. et al. T3DB: the toxic exposome database. Nucleic. Acids. Res., 2015; 43 (Database issue): D928-D934.
  22. Nakamura J., Mutlu E., Sharma V. et al. The endogenous exposome. DNA Repair. (Amst), 2014; 19: 3–13.
  23. Warren J.W., Langenberg P., Clauw D.J. The number of existing functional somatic syndromes (FSSs) is an important risk factor for new, different FSSs. J.Psychosom. Re., 2013; 74 (1): 12–7.
  24. Mc Chesney J.D., Venkataraman S.K., Henri J.T. Plant natural products: Back to the future or into extinction? Phytochemistry, 2007; 68 (14): 2015–22.
  25. Reckeweg H.H. Austauschwirkung, Homotoxine und Krankheitsabschnittean den Geweben der dreiKeimbldtter. MMW Fortschr. Med., 1952; 94 (12): 549–56.
  26. Reckeweg H.H. Homotoxine und Homotoxikosen: GrundlageneinerSynthese der Medizin. 2-ed. Baden-Baden, Germany: Aurelia; 1957.
  27. Medico-Scientific Department. Ordinatio Antihomotoxicaet Materia Medica. Baden-Baden, Germany: BiologischeHeilmittel Heel GmbH; 1986.
  28. Heinle H., Tober C., Zhang D. et al. The lowdose combination preparation Vertigoheel activates cyclic nucleotide pathways and stimulates vasorelaxation. Clin.Hemorheol.Microcirc., 2010; 46 (1): 23–35.